Get the Stockscreener App
40.10
1.37%
0.54
After Hours:
40.10
Edgewise Therapeutics Inc stock is traded at $40.10, with a volume of 511.25K.
It is up +1.37% in the last 24 hours and up +12.67% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$39.56
Open:
$39.39
24h Volume:
511.25K
Relative Volume:
0.37
Market Cap:
$4.31B
Revenue:
-
Net Income/Loss:
$-176.01M
P/E Ratio:
-24.14
EPS:
-1.661
Net Cash Flow:
$-148.97M
1W Performance:
-2.00%
1M Performance:
+12.67%
6M Performance:
+74.80%
1Y Performance:
+207.75%
1-Day Range:
$39.27
$40.60
1-Week Range:
$38.36
$42.02
52-Week Range:
$12.30
$43.93
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
40.10 | 4.37B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Form 4 Edgewise Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant - Stock Titan
[144] Edgewise Therapeutics, Inc. SEC Filing - Stock Titan
Edgewise lures 2 new employees with 16,500 stock options - Stock Titan
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now? - Insider Monkey
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Stocktwits
EWTX News | EDGEWISE THERAPEUTICS INC (NASDAQ:EWTX) - ChartMill
Edgewise Therapeutics, Inc. Actuals & Estimates (NASDAQ:EWTX) - TradingView
(EWTX) Risk Channels and Responsive Allocation - Stock Traders Daily
EWTX Forecast — Price Target — Prediction for 2027 - TradingView
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data - Yahoo Finance
Edgewise Therapeutics stock surges 8.94% to $42.30 as company gears up for EAN poster reveal - Traders Union
Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release - Sahm
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
Edgewise Therapeutics stock hits all-time high at 40.87 USD - Investing.com
Edgewise Therapeutics stock hits all-time high at 40.87 USD By Investing.com - Investing.com Australia
Edgewise Therapeutics stock jumps 5.89 percent as company readies for BIO 2026 event - Traders Union
RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk - Moomoo
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - Moomoo
Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Institutional Confidence - TradingKey
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $41 to $59 - Moomoo
Edgewise Therapeutics (EWTX) director granted 16,377 stock options at $35.59 - Stock Titan
Edgewise Therapeutics (EWTX) director receives grant of 16,377 stock options - Stock Titan
Director at Edgewise (NASDAQ: EWTX) awarded 16,377 stock options - Stock Titan
Edgewise Therapeutics Inc (EWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EWTX Maintained by Goldman Sachs -- Price Target Raised to $32.0 - GuruFocus
RBC Capital raises Edgewise Therapeutics price target on trial data By Investing.com - Investing.com Canada
Edgewise Therapeutics Inc (EWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edgewise shares slip despite positive Phase II HCM data for EDG-7500 - The Pharma Letter
Edgewise Therapeutics Inc (EWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic CardiomyopathySlideshow (NASDAQ:EWTX) 2026-06-17 - Seeking Alpha
Edgewise shares slip after heart-disease drug trial data disappoints investors - 1470 & 100.3 WMBD
Edgewise Therapeutics (NASDAQ: EWTX) grants director equity awards - Stock Titan
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity - Stock Titan
Edgewise Edges Into Phase III With EDG-7500 - Citeline News & Insights
EWTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
EWTX: EDG-7500 showed strong efficacy and safety in HCM, enabling echo-independent dosing - TradingView
Edgewise Therapeutics (EWTX) Shares Plunge 25% After Trial Update - GuruFocus
Edgewise Therapeutics Reports Improvements In Heart Drug Trial - Benzinga
Edgewise heart drug passes key trial test - BioPharma Dive
Edgewise Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co. - Moomoo
Edgewise heads to phase III with solid EDG-7500 data in HCM - BioWorld News
Edgewise Therapeutics (EWTX) Sees Significant Drop in Share Price - GuruFocus
Edgewise Therapeutics reports positive Phase 2 heart data - grafa.com
Edgewise reports phase 2 trial results for heart disease drug By Investing.com - Investing.com South Africa
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Jul 01 '26 |
Sale |
39.41 |
200,000 |
7,881,402 |
24,555 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):